VERAXA combines game changing technologies developed at the EMBL Heidelberg to solve the most prominent challenges in antibody drug development. The VERAXA Biotech Company was founded in 2021 as a fusion of the two EMBL spinoff companies Velabs and Araxa. For further information please visit https://veraxa.com/